Experimental drugs can be entirely prevented Alzheimer’s early onset Alzheimer’s, according to studies, according to a study.
One out of 100 people with this disease develops into middle -aged because they have inherited defective genes from parents known as dominant inherited Alzheimer’s disease (DIAD).
The genes were destined to die from disease until they reached their 60s, with almost 100 %of the possibility of development of Alzheimer’s, the most common form of dementia in their 30s, 40s and 50s.
Currently, researchers in Missouri are testing drugs that do not have disabled disorders of half of these patients.
They used Gantenerumab, a drug that attacked toxic proteins called amyloid in the brain.
Gantenerumab argues that it is no longer developed due to mixed results in the initial study, but the team claims that their studies are the key to hitting the disease.
And the team says their discovery has a wider impact. They believe that the New Testament with similar mechanisms can prevent millions of Alzheimer’s more.
The above intention shows the proportion of Alzheimer’s disease in the US County, 65 and over in 2020.
Doug Whitney, a 75 -year -old naval veteran from Washington, is one of many Americans who inherit the flawless genes that actually guarantee Alzheimer’s disease. But he miraculously avoided the disease. He is being studied by the author of a new study who tests drugs to prevent such patients’ Alzheimer’s.
Gene Presenilin 2 (PSEN2), a gene with a faulty genes, is almost 100 %likely that Alzheimer’s develops, and the findings are ‘exciting results’, researchers said.
The team also suggests that the drug can lead to Alzheimer’s potential treatment to all 7 million Americans who have a disease that meets memory.
Dr. Randall J Bateman, the senior research author of Washu Medicine and Dian Direct, said: ‘I am very optimistic because it can be the first clinical evidence to prevent people who are risk of Alzheimer’s disease.
‘One day, we can delay the onset of millions of dollars of Alzheimer’s disease. “
Alzheimer’s disease is a group of neurological disorders that affect the most common forms of dementia, memory, language, problem solving and other cognitive abilities.
According to the Alzheimer ‘S Association, about 6.7 million Americans live in Alzheimer’s disease in 2023, which is expected to double by 2060.
DIAD accounts for 1 %of the case, the Wash U researchers estimate.
Alzheimer’s bottles are associated with the accumulation of toxic protein beta amyloid and tau, which accumulate in the brain, interfere with neurons and kill brain cells.
People with pSEN2 genes generate excessive levels of these proteins, almost always generating Alzheimer’s.
However, it is still unclear whether Alzheimer’s accumulation or accumulation causes Alzheimer’s symptoms.
The new study, published in Lancet Neurology, looked at 73 adults who inherited defective genes.
All participants have been reduced to the pioneer of dementia, or have been reduced to the underground or very light, and have been 15 to 10 years since the age of Alzheimer’s on the age of family history.
Each person in the study received the liver termab, a monoclonal antibody drug in the development of Hoffmann -La Roche.
Monoclonal antibody drugs are intended to imitate the body’s natural disease fighting antibodies and cause the immune system to attack foreign invaders such as amyloid.
Researchers compared the participants who received Gantenerumab with the placebo participants in the initial exam.
It is assumed that the annual development rate of dementia decreases based on the current ratio (solid line) and dementia incidence rate.
Gantenerumab has received a mixed result in the initial symptoms of Alzheimer’s patients.
For example, after taking the drug for two to three years, the participants who received other drugs or placebo in the previous exam had no change in cognitive function.
As a result, Hoffmann-La Roche in 2023 stopped developing.
However, a new study shows that people who have taken drugs for about eight years have been found, and those who do not have symptoms have reduced their risks in half. A few years before the symptoms appear, treatment may be required in high risk patients.
This study has been limited to the people of Alzheimer’s in the form of genetically, but the authors believe that the results can lead to the prevention and treatment of all patients.
This is because the initial onset and the later onset Alzheimer’s disease starts with amyloids slowly about 20 years before the beginning of the symptoms.
Researchers said that Gan Termab was no longer developed, but similar anti -amyloid drugs were regarded as preventive drugs.
Dr. Bateman said: ‘Everyone in this study was destined to develop Alzheimer’s disease, some of which were not yet.
‘We don’t know how long they will be without symptoms.
‘In order to give the best opportunity to cognitially maintain normal, we have been treating with other anti -amyloid antibodies, hoping that symptoms will not occur at all.
‘What we know is that at least we can delay the development of the symptoms of Alzheimer’s disease and give people a healthier life.’
